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Background: Diabetes mellitus (DM) exacerbates coronary artery disease (CAD) morbidity and mortality.
Mesenchymal stem cells (MSCs) play an important therapeutic role in myocardial ischemic injury. However, little is
known about changes in the cardioprotective characteristics of MSCs from patients with DM.
Methods: Sternal bone marrow aspirates were taken at the time of coronary artery bypass graft surgery. The
morphology and growth characteristics of hMSCs were observed in passage 3. Differences in gene expression
profiling were measured by Affymetrix GeneChipHuman Genome U133 Plus 2.0 Arrays. Forty two adult male rats
with experimentally CAD were randomized into three groups. MSCs from patients with CAD+DM or CAD were
injected into the infarcted myocardium. Control animals received culture medium. Echocardiography, TUNEL,
immunohistochemistry and Western-blot analysis were performed 4 weeks after transplantation.
Results: Growth curves showed that proliferation of hMSCs in the CAD+DM group was significantly lower than in
the CAD group. Nine transcripts of genes related to apoptosis containing Bcl-2 were found to differentiate the two
groups. Transplantation of hMSCs in the infarcted border zone improved cardiac function, but DM partly impaired
this effect. Similar results were observed from TUNEL, immunohistochemistry and Western-blot analysis.
Conclusions: hMSCs from patients with CAD+DM and CAD alone both have proliferative properties.
Transplantation of hMSCs ameliorate heart function, but proliferative ability and myocardial protection decrease
significantly in MSCs obtained from patients with CAD+DM compared with cultures from patients with CAD alone,
possibly as a result of differences in Bcl-2 protein expression and reduced anti-apoptosis.
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Myocardial infarction (MI) and diabetes mellitus (DM)
are serious diseases with high morbidity and mortality. It
was estimated in 2010 that there were almost 1,000,000
patients with MI in the USA, with a 3-year mortality of
nearly 25% [1]. Diabetes mellitus has been widely recog-
nized as a major risk factor for cardiovascular disease,
and carries the same risk of mortality as MI itself [2].
Previous studies have demonstrated that the prognosis* Correspondence: huishanw@126.com
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reproduction in any medium, provided the orof the coronary artery disease (CAD) in patients with
DM is significantly worse than in patients with CAD
alone [3]. However, the mechanisms that underlie this
observation are not fully understood.
Mesenchymal stem cells (MSCs) transplantation has
been widely used as an effective method of protecting
the damaged myocardium and improving cardiac func-
tion [4]. MSCs can be readily isolated from bone mar-
row, adipose tissue, and umbilical cord blood. Ex vivo
experiments indicate that MSCs express CD105, CD73,
CD90, CD29 and CD166, but lack expression of CD45,
CD34, CD14, CD11b, CD79α, CD19 and HLA-DR [5].
It has also been shown that MSCs transplantationThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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including angiogenesis, myogenesis, and inhibition of left
ventricular (LV) remodeling [6]. The paracrine effects of
MSCs have also been highlighted as an important mech-
anism responsible for improving cardiac function [7].
MSCs have been shown to secrete various cytokines,
including vascular endothelial growth factor (VEGF),
and hepatocyte growth factor (HGF), etc [8]. These cyto-
kines play vital roles in paracrine function and contrib-
ute to cardiac repair through mechanisms involving
cytoprotection, neovascularization and inhibition of
apoptosis, all of which minimize ischemic reperfusion
injury [9,10]. The beneficial effects of MSCs transplant-
ation are well documented in both animal and clinical
studies [11-13]. However, it is possible that age and
other risk factors, such as the presence of DM might
reduce the potential for MSCs differentiation and pro-
liferation [14,15]. Age-related changes in MSCs func-
tion have previously been reported [16-18], but to date
little is known about the effects of DM on MSCs
proliferation.
Previous studies have described the biological charac-
teristics of MSCs in a rat model [19] and in patients with
CAD [13]. The present study was undertaken to investi-
gate the differences in the gene expression profile of
MSCs obtained from human subjects with CAD and
DM, and with CAD alone, and to determine if this had
the potential to alter the cardioprotective effect of
hMSCs transplantation against MI in patients with CAD
+DM.
Methods
Isolation and culture of human MSCs
Bone marrow collection for research purpose was ap-
proved by the Ethics Committee of the Shenyang
Northern Hospital, Shenyang City, China. All patients
provided informed consent and the study was conducted
according to the ethical guidelines of the Declaration of
Helsinki (1975).
MSCs were isolated and cultured as previously
reported [13]. Briefly, 3 to 5 mL of bone marrow was as-
pirated from the sternum of patients with CAD who
were undergoing coronary artery bypass graft surgery
(CABG). Patients were divided into CAD+DM and CAD
groups (n = 10 per group). The study inclusion and ex-





Exclusion criterion Infectious, systemdemographic and clinical data are summarized in Table 2.
The diagnosis of DM was based on The American Dia-
betes Association (ADA) diagnostic criteria [20].
Bone marrow aspirates were placed in a 5 mL tube
containing phosphate-buffered saline (PBS) and 1250U
of heparin. The marrow samples were washed twice with
PBS twice after centrifugation at 900 × g for 10 min to
discard the fat layer. The residual cells were added into
the equal volume of 1.073 g/mL Percoll solution in a
50 mL conical tube and centrifuged at 1100 × g/min for
30 min. The mononuclear cells were collected from the
upper layer and interface, diluted with two volumes of
PBS, and collected by centrifugation at 1100 × g/min.
The cells were resuspended in low glucose Dulbecco’s
Modified Eagle Medium (DMEM-LG; Gibco, Grand Isle,
NY, USA) supplemented with 10% fetal bovine serum
(Gibco, Mulgrave, Victoria, Australia), 100U/mL penicil-
lin, and 100 mg/mL streptomycin. The nucleated cells
were plated into 100 mm plastic culture dishes (Beckton
Dickinson, San Jose, CA, USA) and incubated at 37°C in
5% CO2 and 95% humidity. The culture medium was re-
placed by new medium every 3 days. On each occasion,
floating cells or non-adherent hematopoietic cells were
removed. After 12 to 15 days of primary culture, the ad-
herent cells were nearly 80% confluent. The cells were
dissociated using 0.25% trypsin, replated at a ratio of 1:4
in 100 mm plastic culture dishes and grown to near con-
fluence to expand the cells through successive passages.
Growth curves of MSCs from patients were depicted
using the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-dipheny-
ltetrazlium bromide (MTT) assay. Briefly, cells from Pas-
sage 3 were cultured in 96-well plastic culture dishes at
a density of 2.5 × 103cells/well. After 1,2,3,4,5,6,7 and 8 -
days of culture, MTT (Sigma, St. Louis, MO, USA)
dissolved in PBS was added to each well at a final con-
centration of 5 mg/mL, and the samples were incubated
at 37°C for 4 h. Water-insoluble dark blue formazan
crystals formed during MTT cleavage in actively metab-
olizing cells. These were dissolved in dimethyl sulfoxide
(DMSO) (Gibco/Invitrogen, NY, USA). Optical density
was measured at a wave length of 490 nm using a Bio-
Rad 680 microplatereader (Bio-Rad, Califronia, USA)
Phenotype analysis of hMSCs
The hMSCs from Passage 3 were trypsinized, incubated
and stained with mouse anti-human antibody for 30 minand 60 years old
dial infarction with multiple vessels involved
mellitus for over 10 years
ic immunologic diseases, malignancy, hepatic and nephritic dysfunction
Table 2 Patient demographic data
CAD+DM (n = 10) DM (n = 10) P-value
Age, years 54.40 ± 3.10 55.8 ± 1.69 0.226
BMI, kg/m2 26.81 ± 2.74 25.97 ± 4.57 0.624
LVEF,% 43.9 ± 6.72 44.2 ± 4.89 0.910
Smoker, n 7 5 0.157
Hypertension, n 6 8 0.261
Hyperlipidemia, n 3 2 0.158
Target vessel, n
LM 3 2 0.158
LAD 10 10 1.000
LCX 5 6 0.247
RCA 5 6 0.247
OM 5 4 0.247
Diagonal 4 3 0.572
Values are presented as n, or mean ± SD.
BMI body mass index; LVEF left ventricular ejection fraction; LM left main
coronary artery; LAD left anterior descending coronary artery; RCA right
coronary artery; OM obtuse marginal.
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with PBS and resuspended in 500μL PBS after centrifu-
gation at 900 × g. The cells were analyzed using a flow
cytometer (Beckton Dickinson, San Jose, CA,USA). The
antibodies used in this experiment were: CD34-PE,
CD45-PE, CD29-PE and CD44-PE (Beckton Dickinson,
San Jose, CA, USA).
Approximately 5 × 105 cells per 100μL were labeled
with primary mouse antibodies against human CD29,
CD34, CD44 and CD45. Cells were incubated at 4°C for
30 min and washed. Mouse IgG1-PE (Beckton Dickin-
son, San Jose, CA, USA) was used as an isotype control
[21].
Gene expression profiling and protein validation
The hMSCs from Passage 3 were used for RNA ex-
traction. Total RNA (2 μg) from human CAD-MSCs and
CAD+DM-MSCs (n = 3 per group) were used for
microarray analysis. Affymetrix (Santa Clara, USA)
GeneChipHuman Genome U133 Plus 2.0 Arrays, which
allowed analysis of 47,000 transcripts, were performed in
triplicate and analyzed with Affymetrix Microarray Suite
(MAS 5.0). The transcripts were annotated using various
databases to compile a list of apoptosis candidates. All
the experiments of gene expression profiling were au-
thorized to be carried out by CapitalBio Corporation
(Beijing, China).
Gene expression profiling was determined by Western
blot analysis for proteins expressed by selected genes.
Briefly, the hMSCs were treated with cell lysis buffer
(Promega, Madison, WI, USA). Concentration was de-
termined using a BCA protein assay (Pierce, Rockford,
IL, USA). Total proteins (20 μg) were separated using12.5% sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis and transferred to a 0.2 mm nitrocellulose
membrane. The membrane was blocked in PBS buffer
containing 0.2% Tween 20 and 5% non-fat milk for 1 h.
The membrane was then incubated overnight at 4°C
with rabbit Bcl-2 protein polyclonal antibody (1:2000di-
lution; Abcam, Cambridge, MA, USA). Housekeeping
protein β-actin was employed as loading control. Anti-
body binding was detected using horseradish peroxidase
conjugated secondary antibody, and visualized by an
ECL kit (Amersham Biosciences, Piscataway, NJ, USA).
Myocardial infarction formation and hMSCs
transplantation
Male Sprague-Dawley (SD) rats weighing 280 to 300 g
were divided into three groups (CAD+DM group; CAD
group; control group, n = 14 per group). All animals re-
ceived humane care, and all animal protocols complied
with the institution’s guidelines.
Rats were anesthetized by intraperitoneal injection
with pentobarital (50 mg/kg), intubated via an endo-
tracheal cannula and mechanically ventilated. A left lat-
eral thoracotomy was performed. The proximal portion
of the left anterior descending artery was ligated with a
6-0 Prolene (Ethicon, Somerville, NJ, USA) suture.
MSCs from Passage 3 were used for transplantation. The
MSCs were dissociated from the culture dishes with
0.25% trypsin, neutralized with culture medium, washed
with PBS and collected by centrifugation at 900 × g for
5 min at room temperature. The cells were then sus-
pended in culture medium at a concentration of 2 × 106
cells in 50μL and were kept on ice until transplantation.
Animals in the CAD+DM (n = 11) and CAD (n = 9)
groups received a sub-epicardial injection of hMSCs
obtained from patients with CAD+DM and CAD re-
spectively. The cells were injected into the infarcted scar
and adjacent myocardium. The control group (n = 11)
received injections of culture medium into the same
area. Intramuscular penicillin G benzathine (100,000U/kg)
was used to prevent infection. The hMSCs from different
patients were injected respectively. Immunosupprerssion
was provided by daily intramuscular administration of
cyclosporine (10 mg/kg/day; Novartis, Switzerland) for 4 -
weeks post transplantation.
Echocardiography
A blinded investigator performed transthoracic echocar-
diographic studies on the anesthetized rats. Left ventricle
dimension and function were assessed immediately prior
to myocardial infarction, and at 1 and 4 weeks after
hMSCs transplantation. Images were recorded using a
12-MHz high frequency liner phased-array transducer
(Philips SONOS 5500, Bothell, WA, USA). Left ventricu-
lar end diastolic and systolic dimensions were derived
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tained along the para-sternal short-axis view of the left
ventricle at the papillary muscle level. Ejection fraction
(EF) and fractional shortening (FS) were calculated. All
measurements were performed and averaged over three
consecutive cardiac cycles.TUNEL (Terminal Doxynucleotidyl Transferase-mediated
dUTP-x Nick End Labeling) staining
The histochemical detection of apoptotic cells was
performed as previously reported [22]. The tissue blocks
were fixed in 4% paraformaldehyde and incubated with
proteinase K. Fragments of DNA in the tissue sections
were analyzed using a TUNEL detection kit (Promega
Corporation, Madison, WI, USA). For each slide, color
images of 10 separate fields were captured randomly and
digitized. Cells with clear nuclear labeling were defined
as TUNEL-positive cells. The apoptotic index was calcu-
lated as the number of TUNEL-positive cells/ total num-
ber of myocytes.Immunohistochemistry and Western-blot analysis
Myocardial tissue was embedded in paraffin and cut into
5 μm sections. Detection of Bcl-2 expression was
performed as described previously [23]. Tissue sections
were exposed overnight to rabbit Bcl-2 protein poly-
clonal antibody (1:2000 dilution; Abcam, Cambridge,
MA, USA) at 4°C, washed in PBS and incubated with
biotinylated goat anti-rabbit IgG for 60 min at 37°C.
After two washing steps, sections were exposed to
streptavidin-horseradish-peroxidase complex for 30 min
at 37ºCand visualized with 3, 3’-diaminobenzidine, em-
bedded in glycerol gelatin. Images were captured digit-
ally and analyzed using IPP version 6.0. Cytoplasmic
staining was considered positive, and scored as: absent
(-); weakly positive (+), moderately positive (++) or
strongly positive (+++). Myocardial tissue samples were
homogenized in RIPA buffer and the protein expression
of Bcl-2 and VEGF were identified by Western blotting
as described above.Figure 1 Characteristic of hMSCs in Passage-3 and proliferative
abilities of hMSCs between each group. (A) In Passage 3, the
hMSCs from CAD+DM group showed more flattened appearance
and a larger size than those from the CAD group. (B) A MTT assay
was performed and the optical densities of the two groups were
detected at 490 nm. The proliferative potential of MSCs from the
CAD+DM group decreased significantly compared with CAD group
at each time point of the log phase and plateau phase after 2 days
post transplantation (*P < 0.05 vs. CAD group).Statistical analysis
Data were analyzed using SPSS version 12.0 for Win-
dows (SPSS, Chicago, IL, USA). All variables were
presented as means and standard deviations (±SD). The
t-test was used to compare treatments in the in vitro ex-
periments. The results of hMSCs transplantation into
rat models were tested using one-way analysis of
variance. Tukey’s method was used for post-hoc ana-
lysis. Values of P < 0.05 were considered statistically
significant.Results
Growth characteristics of hMSCs
The hMSCs were tightly attached to the culture dishes
after 24 h. They appeared as spindle shaped cells after 3
to 4 days’ culture of the primary passage, after which
they proliferated rapidly. After 12 to 15 days of primary
culture, the hMSCs reached nearly 80% confluences.
The hMSCs in passage 3 from the CAD+DM group had
a more flattened appearance were larger in size than
those from the CAD group (Figure 1A).Proliferative abilities of MSCs from each group
Growth curves were characterized by an initial lag phase
(during the first 2 days) followed by a log phase (from 3
to 7 day) during which cells divided at exponential rates.
This was followed by a plateau phase after Day 8. The
proliferative potential of hMSCs obtained from patients
with CAD+DM was significantly impaired relative to
that seen in cells from patients with CAD (P <0.05).
These differences were apparent at each time point after
Day 2 (Figure 1B).
Liu et al. Cardiovascular Diabetology 2013, 12:40 Page 5 of 10
http://www.cardiab.com/content/12/1/40Phenotype of human MSCs
Human MSCs contained a unique phenotypic popula-
tion which was identified by flow cytometric analysis of
expressed surface antigens. All hMSCs were uniformly
positive for CD29, CD44 and negative for CD34 and
CD45 (Figure 2).
Differences of genes expression profile of hMSCs
between CAD+DM and CAD groups
Three transcripts were dramatically up-regulated
(TNFRSF10B, TNFRSF21, NGF) and six transcripts that
were down-regulated (EPR1, BIRC5, HELLS, BCL2,
TNFRSF1B, CASP1) in the CAD+DM group relative to
the CAD group (Table 3). In addition, expression of Bcl-
2 mRNA was significantly lower in the CAD+DM group
than in the CAD group (Figure 3A).
To confirm the gene expression profile results, Bcl-2
protein was evaluated in vitro and Western bolt analysis
was performed on cell samples at the same time points.
These results also showed that the expression of Bcl-2
protein was significantly lower in the CAD+DM group
than in the CAD group (Figure 3B).
Evaluation of myocardial function
Transplantation of hMSCs into the infarcted border of
zone of rats with experimentally induced CAD signifi-
cantly improved left ventricular function. There were no
remarkable differences in EF and FS between the three
groups preinfarction or at 1 week postinfarction.
In the CAD+DM and CAD groups, both EF and FS in-
creased significantly, relative to the control group, afterFigure 2 The phenotypic nature of human MSCs. The phenotype of hu
CD44 and negative for CD34, CD45.MSC transplantation. However, EF and FS were signifi-
cantly lower in the CAD+DM group than in the CAD
group.
Contractile function was impaired in all three groups
after infarction, but significantly improved after 4 weeks
in animals transplanted with hMSCs (CAD+DM and
CAD groups) relative to values in the control group. Im-
provements in contractile function were significantly less
marked in the CAD+DM group than in the CAD group
(Figure 4).
Myocardial apoptosis after hMSCs transplantation
The degree of apoptosis 4 week after hMSCs transplant-
ation was significantly lower in the CAD+DM and CAD
groups than in the control group. However, myocardial
apoptosis was significantly higher in the CAD+DM
group than in the CAD group (Figure 5).
Protein expression in infarcted myocardium
Protein expression of Bcl-2 following hMSC transplant-
ation in the CAD+DM and CAD groups were both sig-
nificantly higher than in the control group, as evidenced
by immunohistochemical staining and Western-blot ana-
lysis. However, Bcl-2 levels in the CAD+DM were sig-
nificantly lower than in the CAD group. Meanwhile,
VEGF levels in the CAD+DM were also significantly
lower than in the CAD group (Figure 6).
Discussion
The present study demonstrated that hMSCs, isolated
from the sternum had a unique appearance andman MSCs from CAD+DM and CAD groups were positive for CD29,
Table 3 Differential apoptosis-related genes from hMSCs obtained from CAD+DM and CAD
ProbeSet ID Gene title Gene symbol CAD+DM/CAD
206814_at Nerve growth factor(beta polypeptide) NGF 4.1658
209295_at Tumor necrosis factor receptor superfamily, member 10b TNFRSF10B 2.3979
218856_at Tumor necrosis factor receptor superfamily, member 21 TNFRSF21 2.2182
1555826_at Effector cell peptidase receptor 1 (non-protein coding) EPR1 0.2846
202094_at Baculoviral IAP repeat-containing 5 BIRC5 0.1978
203508_at Tumor necrosis factor receptor superfamily, member 1B TNFRSF1B 0.3262
203685_at B-cell CLL/lymphoma 2 BCL2 0.4131
209970_x_at Caspase 1, apoptosis-related cysteine peptidase (interleukin 1, beta, convertase) CASP1 0.3542
220085_at Helicase, lymphoid-specific HELLS 0.4298
Figure 3 Bcl-2 expression in human MSCs. (A) Levels of Bcl-2
expression estimated by Affymetrix microarray analysis show a nearly
2.5-fold down-regulation in CAD+DM-MSCs compared with CAD-
MSCs. (B) Western blot validation of protein levels demonstrated a
great than 2-fold down-regulation in CAD+DM-MSCs compared with
CAD-MSCs. (*P < 0.05 vs. CAD group).
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marrow. A previous study demonstrated that hMSCs
from Passage 1 to 5 had significantly greater proliferative
potential than those from later passages [13]. We there-
fore chose hMSCs from Passage 3 for all our in vitro
and in vivo experiments.
We demonstrated there was a significant difference in
proliferation and gene expression profiling of hMSCs de-
rived from patients with CAD+DM relative to those de-
rived from patients with CAD only. These findingsFigure 4 Evaluation of myocardial function. Ejection fraction EF
(A) and fractional shortening FS (B) were not significantly changed
in any of the three groups at 1 week post infarction. However, EF
and FS increased significantly in CAD+DM and CAD groups after
MSC transplantation. EF and FS were significantly lower in the CAD
+DM group than in the CAD group after 4 weeks. (*P < 0.05 CAD
+DM and CAD groups compared with control group, #P < 0.05 CAD
+DM group compared with CAD group).
Figure 5 Myocardial apoptosis 4 weeks after cells transplantation. Myocardial apoptosis was detected by TUNEL staining. TUNEL-positive
cells (TP indicated) decreased significantly in CAD+DM and CAD groups compared with control group. However, the number of TUNEL-positive
cells was significantly higher in the CAD+DM group than in the CAD group. (*p < 0.05 vs. control group, #P < 0.05 vs. CAD group).
Figure 6 Protein expression in infarcted myocardium. (A) Immunohistochemical detection of Bcl-2 expression in infarcted myocardium from
control (+), CAD+DM (++) and CAD (+++) groups. (B) Western-blot analysis shows that hMSCs transplantation from patients with CAD+DM and
CAD significantly increased Bcl-2 expression in the myocardium compared with the control group. However, Bcl-2 protein level was significantly
lower in the CAD+DM group than in the CAD group. (C) Western-blot analysis shows that VEGF expression after hMSCs transplantation in CAD
+DM group was significantly lower than in the CAD group. (*P < 0.05 vs. control group, #P < 0.05 vs. CAD group).
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tion of hMSCs in vitro. The current results were consist-
ent with previous reports in which they found that
endothelial progenitor cells were depleted even in DM
patients without clinical evidence of macrovascular
disease [24]. We also showed that Bcl-2 as well as other
differential genes may play a crucial role in hMSC prolif-
eration. The other important finding was that trans-
plantation of hMSCs from CAD patients into rats with
experimentally induced myocardial infarction improved
cardiac contractility and attenuated apoptosis of cardio-
myocytes. These effects were also weakened in MSCs
derived from patients with CAD+DM, possibly due in
part to reduced expression of Bcl-2 in these cells. These
results were consistent with those from a previous study
using a rat model [19].
In our study, we identified several differentially
expressed genes related to apoptosis. From differential
genes, TNFRSF10B, TNFRSF21 and TNFRSF1B are a
member of the TNF-receptor superfamily, which deliver
signals for cell death, survival, proliferation and differen-
tiation. However, their effects on apoptosis are diverse.
TNFRSF10B, TNFRSF21 can be activated by tumor ne-
crosis factor-related apoptosis inducing ligand and trans-
ducer apoptosis signals. In contrast, TNFRSF1B plays a
vital role in preventing apoptosis [25]. Moreover, BIRC5,
which positively correlated with the expression of Bcl-2,
is a member of the inhibitor of apoptosis gene family
and take part in the prevention of apoptotic cell death
[26]. From all the differential genes related to apoptosis,
Bcl-2 was selected for further study since our previous
studies demonstrated that Bcl-xl gene transfer has a car-
dioprotective function against ischemia/reperfusion injury
[27,28]. Both Bcl-2 and Bcl-xl belong to the Bcl-2 family,
and are overexpressed in B-cell lymphoma [29]. Bcl-2 fam-
ily of proteins acts as critical regulators of pathways in-
volved in anti-apoptosis and inhibition of cell death [30]. It
has also been shown that Bcl-2 contributes to cardiac pro-
tection during ischemic conditions, where it acts as one of
the regulators of the metabolic functions of mitochondria
[31]. In the present study, mRNA and protein expression
of Bcl-2 were significantly lower in the CAD+DM group
than in the CAD group, suggesting that Bcl-2 expression
in patients with CAD might be impaired by DM.
MSCs exhibit the property of immune-tolerance where-
by they express low levels of major histocompatabilty
complex (MHC) and co-stimulant molecules [32]. This
means that MSCs are generally safe and effective when
used for allo-transplantion [11]. However, post-transplant
rejection has previously been reported in a xenogenic
model [33], and for this reason we used, cyclosporine to
suppress the immune response in our study.
We also showed that hMSCs transplantation improved
myocardial but that the improvement was significantlymore marked with cells derived from patients with CAD
than with those derived from patients with CAD+DM.
The findings that MSCs transplantation improves heart
function after myocardial infarction and that DM may
weaken myocardial protective function of hMSCs trans-
plantation significantly are in accordance with previous
studies [13,34]. In our study, myocardial tissue from the
infarcted zone and border was determined by TUNEL,
imunohistochemistry and Western-blot analysis. We
found that apoptosis of myocardial cells increased dra-
matically in CAD+DM group compared with CAD
group, in accordance with a previous study in a rat
model [19]. We also showed that, expression of Bcl-2
decreased markedly in the CAD+DM group compared
with CAD group. Previous studies revealed a reduced
expression of VEGF in the myocardium in diabetes [35].
However, there is no difference between the two groups
at mRNA level in Gene Chip results of cultured hMSCs.
On the contrary, protein expression of VEGF after
hMSCs transplantation decreased significantly in the
CAD+DM group compared with CAD group. This
might be due to the elevated VEGF secretion induced by
high-level expression of Bcl-2 in response to hypoxic
condition [36]. Thus, different levels between protein
and mRNA expression existed in cell culture under
normoxic condition and infarcted myocardium under
hypoxic condition. Thus, inhibition of Bcl-2 expression
may result in increased apoptosis which in turn de-
creases myocardial protection; decreased secretion of
VEGF may one of the possible reasons. It has been
shown that the function of MSCs can be modulated by
introduction of specific genes. [36]. It is therefore pos-
sible that hMSCs from CAD+DM patients modified with
Bcl-2 gene may have improved expression levels of Bcl-2
protein and enhanced ability to protect the ischemic
myocardium. At the same time, the method of human
stem cell based three dimensional microtissues may also
represent a translational therapy strategy which may en-
hance cellular retention, survival and integration [37].
Both of above can be studied in deep-going way in the
future.Limitations
Previous studies have demonstrated that aging impairs
the quantity, quality and mobilization capacity of MSCs
[14,38]. Thus, hMSCs were obtained from patients 50 to
60 years of age, which limited the number of relative
younger patients with CAD+DM. This may have com-
promised the capacity of MSCs to offer myocardial pro-
tection. The relatively small sample size in our study
may also have impacted our results to some extent. Our
findings therefore need to be substantiated in larger
populations of patients of different age groups.
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The present study indicates that hMSCs from patients
with CAD+DM and CAD have proliferative properties,
and that transplantation of hMSCs from all patients
improved heart function in rats with experimentally-
induced myocardial infarction. The ability to proliferate
and preserve myocardial function decreased significantly
in MSCs obtained from patients with CAD+DM com-
pared with those obtained from patients with CAD. The
differential effects of transplantation of different human
MSCs might result from differences of Bcl-2 protein ex-
pression, which determine the extent of anti-apoptosis.
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